ATE15798T1 - Heterozyklische carboxamide, zubereitungen, die solche verbindungen enthalten, verfahren zu ihrer herstellung und methoden zur behandlung damit. - Google Patents

Heterozyklische carboxamide, zubereitungen, die solche verbindungen enthalten, verfahren zu ihrer herstellung und methoden zur behandlung damit.

Info

Publication number
ATE15798T1
ATE15798T1 AT82850032T AT82850032T ATE15798T1 AT E15798 T1 ATE15798 T1 AT E15798T1 AT 82850032 T AT82850032 T AT 82850032T AT 82850032 T AT82850032 T AT 82850032T AT E15798 T1 ATE15798 T1 AT E15798T1
Authority
AT
Austria
Prior art keywords
compounds
preparation
methods
treatment
processes
Prior art date
Application number
AT82850032T
Other languages
German (de)
English (en)
Inventor
Edgar Eriksoo
Eva Britt-Marie Sandberg
Lars Johan Torbjoe Stalhandske
Original Assignee
Leo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Ab filed Critical Leo Ab
Application granted granted Critical
Publication of ATE15798T1 publication Critical patent/ATE15798T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
AT82850032T 1981-03-03 1982-02-22 Heterozyklische carboxamide, zubereitungen, die solche verbindungen enthalten, verfahren zu ihrer herstellung und methoden zur behandlung damit. ATE15798T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8106594 1981-03-03
EP82850032A EP0059698B1 (en) 1981-03-03 1982-02-22 Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith

Publications (1)

Publication Number Publication Date
ATE15798T1 true ATE15798T1 (de) 1985-10-15

Family

ID=10520089

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82850032T ATE15798T1 (de) 1981-03-03 1982-02-22 Heterozyklische carboxamide, zubereitungen, die solche verbindungen enthalten, verfahren zu ihrer herstellung und methoden zur behandlung damit.

Country Status (21)

Country Link
US (2) US4547511A (enExample)
EP (1) EP0059698B1 (enExample)
JP (1) JPS57171975A (enExample)
KR (1) KR860001876B1 (enExample)
AT (1) ATE15798T1 (enExample)
AU (1) AU547849B2 (enExample)
CA (1) CA1182455A (enExample)
DE (1) DE3266464D1 (enExample)
DK (1) DK157859C (enExample)
ES (1) ES510042A0 (enExample)
FI (1) FI79532C (enExample)
GR (1) GR76073B (enExample)
HK (1) HK38689A (enExample)
HU (1) HU186909B (enExample)
IE (1) IE52670B1 (enExample)
IL (1) IL65028A (enExample)
NO (1) NO163130C (enExample)
NZ (1) NZ199888A (enExample)
PH (1) PH18520A (enExample)
PT (1) PT74512B (enExample)
ZA (1) ZA821210B (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269753A (en) * 1964-08-31 1966-08-30 Data Man Inc Bookkeeping unit
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4400017A (en) * 1981-03-04 1983-08-23 Pendergrass Russell G Integrated budget and check record book
US4650804A (en) * 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
DE3420116A1 (de) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
SE8902076D0 (sv) * 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
US5691350A (en) * 1990-02-22 1997-11-25 Kabi Pharmacia Ab Use of linomide for treatment of retrovirus infections specifically HIV infections
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
US5504092A (en) * 1990-03-27 1996-04-02 Pharmacia Ab Use of Linomide to increase hemopoietic cell precursors
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use
CA2091171A1 (en) * 1990-09-07 1992-03-08 Adriano Afonso Antiviral compounds
EP0549729B1 (en) * 1990-09-07 1997-12-17 Schering Corporation Antiviral compounds and antihypertensive compounds
WO1992004328A1 (en) * 1990-09-07 1992-03-19 Schering Corporation Antiviral compounds and antihypertensive compounds
US5219864A (en) * 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
TW222276B (enExample) * 1992-01-27 1994-04-11 Fujisawa Pharmaceutical Co
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
GB9311562D0 (en) * 1993-06-04 1993-07-21 Fujisawa Pharmaceutical Co Heterocyclic derivatives
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
CN1215835C (zh) * 1996-03-27 2005-08-24 东丽株式会社 酮衍生物及其在医学上的应用
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
JP2000044560A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ベンゾキノリジン誘導体及びその製造方法
JP2000044561A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ピロロキノリン誘導体及びその製造方法
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
US6395750B1 (en) 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
RU2240313C2 (ru) * 1999-10-25 2004-11-20 Эктив Байотек Аб Лекарственные средства для лечения злокачественных опухолей
WO2001034570A1 (en) * 1999-11-08 2001-05-17 Sankyo Company, Limited Nitrogenous heterocycle derivatives
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
JP2003012667A (ja) * 2001-06-26 2003-01-15 Rrf Kenkyusho:Kk キノリンカルボキサミド骨格を有する抗菌剤
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
WO2004104000A1 (ja) * 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US7228698B2 (en) * 2005-06-30 2007-06-12 Premark Feg L.L.C. Refrigeration unit
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US7884208B2 (en) * 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
JP5202327B2 (ja) * 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
EP2035001B1 (en) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
US8552194B2 (en) * 2008-04-28 2013-10-08 Actavis Group Ptc Ehf Process for preparing quinoline-3-carboxamide derivatives
UA104005C2 (ru) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
RS53460B (sr) 2008-10-23 2014-12-31 Vertex Pharmaceuticals Incorporated Modulatori regulatora cistično fibrozne transmembranske provodnosti
WO2010059549A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
EP2376456A2 (en) * 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
KR20120045032A (ko) * 2009-07-30 2012-05-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 크론병의 치료
SI2467372T1 (sl) * 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
AU2011223702B2 (en) * 2010-03-03 2016-07-14 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
PH12012501739A1 (en) * 2010-03-03 2017-08-23 Teva Pharma Treatment of lupus nephritis using laquinimod
PT2542079E (pt) * 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
AU2011274502A1 (en) * 2010-07-09 2013-02-28 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
BR112013007850A2 (pt) * 2010-10-14 2016-06-07 Immunahr Ab 1,2-diidro-4-hidróxi-2-oxo-quinolina-3-carboxanilidas como ativadores de ahr
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
BR112015021602A2 (pt) 2013-03-14 2017-07-18 Teva Pharma cristais de laquinimod de sódio e processo melhorado para a fabricação dos mesmos
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
CN109843870A (zh) 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
GB202006390D0 (en) 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
JP2023527782A (ja) * 2020-05-21 2023-06-30 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びその使用
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
TWI838849B (zh) 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
KR20250095720A (ko) 2022-10-31 2025-06-26 일라이 릴리 앤드 캄파니 Ahr 효능제
CN120225518A (zh) 2022-11-15 2025-06-27 伊莱利利公司 Ahr激动剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471784A (de) * 1966-01-26 1969-04-30 Bayer Ag Verfahren zur Herstellung von Carbostyrilderivaten
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
CH578534A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578535A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578536A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578537A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
US3917609A (en) * 1973-06-27 1975-11-04 Minnesota Mining & Mfg Pyrroloquinoline carboxylic acids and derivatives
FR2281761A1 (fr) * 1974-08-13 1976-03-12 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation

Also Published As

Publication number Publication date
NO820642L (no) 1982-09-06
AU547849B2 (en) 1985-11-07
EP0059698B1 (en) 1985-09-25
KR860001876B1 (ko) 1986-10-24
DK81282A (da) 1982-09-04
GR76073B (enExample) 1984-08-03
JPS57171975A (en) 1982-10-22
US4738971A (en) 1988-04-19
DK157859B (da) 1990-02-26
IL65028A0 (en) 1982-04-30
ZA821210B (en) 1983-01-26
FI79532C (fi) 1990-01-10
DK157859C (da) 1990-07-30
US4547511A (en) 1985-10-15
IL65028A (en) 1986-11-30
FI820728L (fi) 1982-09-04
NO163130B (no) 1990-01-02
EP0059698A1 (en) 1982-09-08
CA1182455A (en) 1985-02-12
AU8107682A (en) 1982-09-09
KR830009037A (ko) 1983-12-17
NZ199888A (en) 1985-07-31
ES8400409A1 (es) 1983-10-16
DE3266464D1 (en) 1985-10-31
HU186909B (en) 1985-10-28
IE820314L (en) 1982-09-03
FI79532B (fi) 1989-09-29
PT74512A (en) 1982-04-01
HK38689A (en) 1989-05-19
PT74512B (en) 1983-11-08
ES510042A0 (es) 1983-10-16
IE52670B1 (en) 1988-01-20
JPH049786B2 (enExample) 1992-02-21
PH18520A (en) 1985-08-02
NO163130C (no) 1990-04-11

Similar Documents

Publication Publication Date Title
ATE15798T1 (de) Heterozyklische carboxamide, zubereitungen, die solche verbindungen enthalten, verfahren zu ihrer herstellung und methoden zur behandlung damit.
DE69018601D1 (de) Konzentrate von aktiven Verbindungen und Kombinationen von aktiven Verbindungen, ihre Verfahren zur Herstellung und Arzneimittel, die die Konzentrate oder die Kombinationen enthalten.
DE3883080D1 (de) Legierungspulvergemisch zur behandlung von legierungen.
ATE45153T1 (de) Benzisoselenazolthione, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische produkte.
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
ATE324T1 (de) Hydroxypropyl-triazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
ATE10582T1 (de) Verfahren zur herstellung pharmazeutischer, darmloeslicher kapseln.
OA06797A (fr) Composé de platine, procédé de préparation et compositions pharmaceutiques en contenant.
DE3575725D1 (de) Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
ES432848A2 (es) Procedimiento para la obtencion de derivados de alcanolami- na.
ES483661A1 (es) Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos
DE3787437D1 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.
NL7711414A (nl) Werkwijze ter bereiding van n-gesubstitueerde lactamen, alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten.
PT69999A (de) 1,2,3-triazolcarbonsaureamide verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel
SE8404334D0 (sv) 16-fluoro-16,17-didehydro-prostanoids and process for their preparation
ATE65778T1 (de) 4-oxo-thiazolidin-2-yliden-acetamid-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel zur bekaempfung von erkrankungen des zentralnervensystems.
PT79928B (de) Verfahren zur herstellung von 1,3,2-dioxaborinan und von bioziden verbindungen die sie enthalten
ATA213579A (de) Verfahren zur herstellung von neuen, diuretisch wirksamen steroid-spiro- oxazolidinon-derivaten en und von aus diesen verbindungen bereiteten arznei- mitteln
OA07171A (fr) Spirothiazolidineone, son procédé de préparation et préparation pharmaceutique la contenant.
ATE1583T1 (de) Neue 1,4-dihydropyridazin-3-carbonylverbindungen, verfahren zu ihrer herstellung, die verbindungen zur verwendung bei der behandlung von krankheiten, diese enthaltende arzneimittel und verfahren zur herstellung der arzneimittel.
ATE11911T1 (de) N-(1-allyl-2-pyrrolidinyl-methyl)-2-methoxy-4amino-5-methylsulfamoyl-benzamide, verfahren zur herstellung und verwendung als heilmittel.
ATE69809T1 (de) Leukotrienantagonisten, verfahren zu ihrer herstellung, ihre anwendung zur behandlung von krankheiten.
PT76582B (de) 1,2,4-triazol-1-yl-propionitrile verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel
EP0158299A3 (de) Substituierte Phenylethylderivate, Verfahren zu ihrer Herstellung und pharmazeutische Mittel
EP0137499A3 (de) Verfahren zur Gewinnung von beta-Elemonsäure und diese enthaltende pharmazeutische Zubereitungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee